Literature DB >> 17761207

Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha.

Josh Q H Wu1, Nicole D Barabé, Ying-Min Huang, George A Rayner, Mary E Christopher, Fay L Schmaltz.   

Abstract

Western equine encephalitis virus (WEEV) is a positive-sense, single-stranded RNA virus which is transmitted to equines and humans through mosquito bites. WEEV infects the central nervous system with severe complications and even death. There are no human vaccine and antiviral drugs. We investigated whether adenovirus-mediated expression of interferon alpha could be used for pre- and post-exposure protection against a lethal WEEV challenge in mice. A human adenoviral vector (Ad5-mIFNalpha) expressing mouse interferon alpha was constructed. We found that Ad5-mIFNalpha provided 100% protection against various WEEV strains in mice after a single intramuscular inoculation at 24 h, 48 h or 1 week before the challenge. When given as a single inoculation at 6 h after the challenge, Ad5-mIFNalpha delayed the progress of WEEV infection and provided about 60% protection. Our findings suggest that adenovirus-mediated expression of interferon alpha can be an alternative approach for the prevention and treatment of WEEV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17761207     DOI: 10.1016/j.virol.2007.07.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Buggy Creek virus (Togaviridae: Alphavirus) upregulates expression of pattern recognition receptors and interferons in House Sparrows (Passer domesticus).

Authors:  Carol A Fassbinder-Orth; Virginia A Barak; Ellecia L Rainwater; Ashley M Altrichter
Journal:  Vector Borne Zoonotic Dis       Date:  2014-05-27       Impact factor: 2.133

3.  Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.

Authors:  Dale L Barnard; Yohichi Kumaki
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

4.  Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model.

Authors:  Justin G Julander; Jane Ennis; Jeffrey Turner; John D Morrey
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

Review 5.  Encephalitic alphaviruses.

Authors:  Michele A Zacks; Slobodan Paessler
Journal:  Vet Microbiol       Date:  2009-08-28       Impact factor: 3.293

6.  Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs.

Authors:  Xiangguo Qiu; Gary Wong; Lisa Fernando; Jane Ennis; Jeffrey D Turner; Judie B Alimonti; Xiaojian Yao; Gary P Kobinger
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

7.  Evaluation of Different Strategies for Post-Exposure Treatment of Ebola Virus Infection in Rodents.

Authors:  Jason S Richardson; Gary Wong; Stéphane Pillet; Samantha Schindle; Jane Ennis; Jeffrey Turner; James E Strong; Gary P Kobinger
Journal:  J Bioterror Biodef       Date:  2011-10-20

Review 8.  Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Authors:  Azizul Haque; Didier Hober; Joel Blondiaux
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

9.  Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates.

Authors:  Gary Wong; Jason S Richardson; Stéphane Pillet; Ami Patel; Xiangguo Qiu; Judie Alimonti; Jeff Hogan; Yi Zhang; Ayato Takada; Heinz Feldmann; Gary P Kobinger
Journal:  Sci Transl Med       Date:  2012-10-31       Impact factor: 17.956

10.  Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201).

Authors:  Ashley Dagley; Jane Ennis; Jeffrey D Turner; Kerry A Rood; Arnaud J Van Wettere; Brian B Gowen; Justin G Julander
Journal:  Antiviral Res       Date:  2014-05-14       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.